The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Until the company is out of money there's no stick to force us to sell....no idea where you get forced buyout ideas from. Cut down on the caffeine before bed.
Bline, and yep...I'm filtering more and more so the group chat is lots of green boxes. I learn as much from the volume of green boxes as I do from the regurgitation. But all the better for it. Patience is what's needed right now...once we get to mid-year I'll start allowing myself to get a little thoughtful and excited about what's ahead. I'm happy to be surprised with unexpected good news RNSes, I'm just not expecting it until we are close to needles in arms.
The one things that is nagging me though is...where is Prevail in all of this...zero mention of them at all for a while feels a little odd.
Haywain,
A query for you based on your relevant expertise. If the CART treatment works in a patient…do you expect this to be something that is noticeable in a day? A week? A month? I’m not scientific so picturing these little CARTs floating around the bloodstream, but can’t quite picture how quick or slow things might develop. Eg is it if no noticeable reduction in cancer cells after a week does that mean it doesn’t work or are the CARTs still building their army internally type stuff. Would you expect it is one and done or multiple repeat treatments? Yes I know this is phrased very untechnically I’m not trying to pretend I have a clue.
Digittt
Goldwater...the market sounding deck had a number targetted for the raise and mentioned 1 patient. The covering email that it was attached to though suggested ~3 (and I asked them why the difference between doc and cover email, didn't get an answer). Then the raise came in at a larger amount and it suggested to me that 3 was likely tied to them raising more than the initial target which they did. That's the info I'm working on. You can choose whether or not you want to believe me, I don't care...if you want to play conspiracy games and if you decide I'm making the above up....am I ramping or deramping? Good luck with figuring that out.
MrI...you've also said you've got 14 millions shares before. Seems out of whack with your repetitive mopiness and criticism of the company leadership. It seems obvious this is not the share for you but it must be since you're still here. Secretly I think you enjoy punishing yourself. Can I recommend you rather shove all your money in Tesla and follow Elon on Twitter. You get even more failed timelines and many more conspiracy theories for your buck.
Pumpky, if that’s a dig at me that’s as dumb and desperate as it gets. I got the market sounding the day before / day of. All of that is done on a confidential basis and I wasn’t allowed to trade or share info until it was public. Dont play by the rules and the best case is you don’t get invited to the next one…worst case you get yourself into trouble. I hadn’t bought or sold any HEMO since last year sometime….until this week where I bought a little ahead of ISA year end and given I’m hoping we are near the floor.
Haywain....just to provide some other feedback. The market sounding had a lower raise amount "penciled" in and it suggested 1 patient treated (and as before H2 was touted for testing). The email though that came with the sounding suggested 1-3 patients...I queried the discrepancy. I didn't get a direct response though, but it was answered indirectly ultimately with the amount raised being higher than what was touted in the sounding. ~5 patients seems a possibility to me with the amount raised. To get going with the testing they had to establish a clinical site at UPenn. Contract an external provider for the testing and develop the test for inclusion / exclusion in the trial...and they had to recruit the patients. That is what they are presumably busy with now.
Absent unexpected news out of the company, I struggle to see much movement until we start hearing bits about progress towards injections. A question for those who have better memories...am I mis-remembering that Prevail were involved in CAR-T trials? I had it in my head they were and then someone posted some comment here about them being linked rather to CBR.
Day before / day of the raise. And no I did not / would not trade. I also didn’t put money in because I guessed the knock on implication of such a crappy price would mean the share price sucking for the next while. So I have plenty of time to decide whether to stick more money in at or around the same price.
Moors...within a few minutes of receiving I went back saying the pricing was wrong (gave them an out by pretending it was square bracketed and clearly going to be higher...I knew it wasn't) . I gave them my reasons and noted every single shareholder would feel the same. I reinforced what I felt were gaps in the marketing doc that created concerns - I highlighted that those concerns were raised because they cut-off the goodwill with the pricing. I would have overlooked them if I felt they were appropriately managing pricing. I was livid because I knew immediately what it meant for the next 4 to 8 months and...I don't believe the markets are that tough. I've seen equity purse strings being opened in tech this year (not bio so I know not the same) and last year they were definitely closed.
At heart though...I do trust Vlad. So, after all is said and done and after another raise that's not right...we do have enough to get to the first patient possibly even 2 or 3. And any positive story there will make us forget this raise.
If you want to be reflective fully…I was in the tent on the sounding but when they told me the price I said no. I believe in the company and if it was higher I might have taken part. I think I’ve said that all before. But when it was pitched I knew immmediately I’d be able to buy shares cheaper than the issue price. Thats what makes me so bleeding angry. If the price had been more smartly managed we would be 25% higher for the next x months until the trials.